Riggs Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-10
Closed 341
2022
Q3
$0 Hold
10
﹤0.01% 336
2022
Q2
$0 Hold
10
﹤0.01% 317
2022
Q1
$0 Hold
10
﹤0.01% 332
2021
Q4
$1K Hold
10
﹤0.01% 307
2021
Q3
$1K Hold
10
﹤0.01% 305
2021
Q2
$1K Hold
10
﹤0.01% 305
2021
Q1
$1K Hold
10
﹤0.01% 276
2020
Q4
$1K Buy
+10
New +$1.33K ﹤0.01% 263
2020
Q3
Sell
-10
Closed -$3K 200
2020
Q2
$3K Hold
10
﹤0.01% 215
2020
Q1
$0 Hold
10
﹤0.01% 270
2019
Q4
$0 Hold
10
﹤0.01% 302
2019
Q3
$0 Hold
10
﹤0.01% 253
2019
Q2
$0 Hold
10
﹤0.01% 264
2019
Q1
$0 Hold
10
﹤0.01% 253
2018
Q4
$1K Hold
10
﹤0.01% 229
2018
Q3
$0 Hold
10
﹤0.01% 244
2018
Q2
$0 Hold
10
﹤0.01% 260
2018
Q1
$1K Hold
10
﹤0.01% 266
2017
Q4
$1K Hold
10
﹤0.01% 259
2017
Q3
$1K Hold
10
﹤0.01% 255
2017
Q2
$1K Hold
10
﹤0.01% 277
2017
Q1
$1K Hold
10
﹤0.01% 258
2016
Q4
$1K Hold
10
﹤0.01% 251
2016
Q3
$1K Hold
10
﹤0.01% 255
2016
Q2
$1K Hold
10
﹤0.01% 250
2016
Q1
$1K Hold
10
﹤0.01% 244
2015
Q4
$1K Hold
10
﹤0.01% 251
2015
Q3
$1K Hold
10
﹤0.01% 245
2015
Q2
$1K Hold
10
﹤0.01% 291
2015
Q1
$1K Hold
10
﹤0.01% 283
2014
Q4
$1K Buy
+10
New +$1.22K ﹤0.01% 279

Other funds holding INO

Riggs Asset Management's INO Position: Q4 2022 in Review

Riggs Asset Management sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 10 shares.

Riggs Asset Management first reported a position in INO in Q4 2014 and held it in 31 quarters. The position peaked at $3K in Q2 2020. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

  • Riggs Asset Management reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Riggs Asset Management sold 10 Inovio Pharmaceuticals shares in Q4 2022.
  • Riggs Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2014 and held it in 31 quarters.
  • Riggs Asset Management's Inovio Pharmaceuticals position peaked at $3K in Q2 2020.
  • 183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Riggs Asset Management's 13F filing for Q4 2022, filed 30 Jan 2023.